Identifying genetic variants linked to nerve damage in breast cancer patients treated with paclitaxel

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on using whole exome sequencing to analyze germline DNA samples from patients with peripheral neuropathy who have received paclitaxel for breast cancer. The primary goal is to identify rare genetic variants that may increase the risk of developing peripheral neuropathy, particularly in patients of African and European descent. By examining previously collected DNA samples, researchers aim to uncover biomarkers that could help predict which patients are more susceptible to nerve damage from chemotherapy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* European American patients with DNA available and designated case or control
* African American patients with DNA available and designated case or control status
* Patients who developed grade 2-4 for African American (AA) and grade 3-4 for European American (EA) peripheral neuropathy during their treatment with paclitaxel and who did not develop peripheral neuropathy following a full course of treatment with paclitaxel

Where it's running

• Eastern Cooperative Oncology Group
  Boston, Massachusetts, United States Recruiting

Study contacts

• Principal investigator: Bryan P Schneider — Eastern Cooperative Oncology Group

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Home-use Erchonia EVRL laser for temporary relief of idiopathic peripheral neuropathy foot pain

  This study will test whether a home-use Erchonia EVRL laser can provide temporary relief of foot pain for adults with idiopathic peripheral neuropathy.

  Recruiting Erchonia Corporation · Miramar, Florida · NCT06912646

• Mobile health navigation to improve breast cancer screening in Kenyan women

  This study tests m-Health patient navigation tools to help women in Kenya access breast cancer screening and early detection services.

  Recruiting Emory University · Atlanta, Georgia · NCT07764796

• Blended e-Health Program to Help Women with Breast or Gynecologic Cancer Manage Fear of Cancer Progression

  This trial tests a blended online and group program to see if it helps women with breast or gynecologic cancer feel less fear that their cancer could grow or spread.

  Recruiting at 11 sites City of Hope Medical Center · Arcadia, California and 10 other locations · NCT07741968

• Environmental exposure checks in high-risk and early-onset breast cancer care

  This study tests how patients and providers feel about using environmental exposure risk data in breast cancer care for women at average/high risk or with early-onset breast cancer.

  Recruiting City of Hope Medical Center · Duarte, California · NCT07690852

• CSF sample collection from people with metastatic breast cancer to see brain metastasis risk

  This study tests whether spinal fluid and other samples can help predict brain metastases in adults with metastatic HER2-positive or triple-negative breast cancer who have not yet shown brain involvement.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07619534

• Body composition and outcomes after breast reconstruction

  This study will see if detailed body composition measurements can help predict complications after mastectomy with immediate breast reconstruction in adult women.

  Recruiting University of California, San Francisco · San Francisco, California · NCT07546331

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.